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A Ab bs st tr ra ac ct t
B Ba ac ck kg gr ro ou un nd d: : The need for an integrated view of data obtained from high-throughput technologies
gave rise to network analyses. These are especially useful to rationalize how external
perturbations propagate through the expression of genes. To address this issue in the case of
drug resistance, we constructed biological association networks of genes differentially expressed
in cell lines resistant to methotrexate (MTX).
M Me et th ho od ds s: : Seven cell lines representative of different types of cancer, including colon cancer
(HT29 and Caco2), breast cancer (MCF-7 and MDA-MB-468), pancreatic cancer (MIA PaCa-2),
erythroblastic leukemia (K562) and osteosarcoma (Saos-2), were used. The differential expres-
sion pattern between sensitive and MTX-resistant cells was determined by whole human genome
microarrays and analyzed with the GeneSpring GX software package. Genes deregulated in
common between the different cancer cell lines served to generate biological association
networks using the Pathway Architect software.
R Re es su ul lt ts s: : Dikkopf homolog-1 (DKK1) is a highly interconnected node in the network generated
with genes in common between the two colon cancer cell lines, and functional validations of this
target using small interfering RNAs (siRNAs) showed a chemosensitization toward MTX.
Members of the UDP-glucuronosyltransferase 1A (UGT1A) family formed a network of genes
differentially expressed in the two breast cancer cell lines. siRNA treatment against UGT1A also
showed an increase in MTX sensitivity. Eukaryotic translation elongation factor 1 alpha 1
(EEF1A1) was overexpressed among the pancreatic cancer, leukemia and osteosarcoma cell lines,
and siRNA treatment against EEF1A1 produced a chemosensitization toward MTX.
C Co on nc cl lu us si io on ns s: : Biological association networks identified DKK1, UGT1As and EEF1A1 as important
gene nodes in MTX-resistance. Treatments using siRNA technology against these three genes
showed chemosensitization toward MTX.
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The large amount of information obtained with high-
throughput technologies like expression microarrays needs
to be processed in order to be comprehensible to molecular
biologists. In this regard, many computational methods have
been developed to facilitate expression data analysis. Gene
clustering, gene ontology and pathway analyses are
commonly used [1,2]. Pathways are manually generated dia-
grams that represent knowledge on molecular interactions
and reactions [3] and they can be used to visualize the
involvement of the differentially expressed genes in specific
molecular, cellular or biological processes. However, the
complexity of higher organisms cannot be explained solely
as a collection of separate parts [4]; in organisms, pathways
never exist in isolation, they are part of larger networks,
which are more informative and real [5]. Gene networks are
capable of describing a large number of interactions in a
concise way, and provide a view of the physiological state of
an organism at the mRNA level. Biochemical networks can
be constructed at several levels and can represent different
types of interactions. Literature mining allows the extraction
of meaningful biological information from publications to
generate networks [6]. Taking into account the progress in
gene expression profiling, elucidating gene networks is an
appropriate and timely step on the way to uncovering the
complete biochemical networks of cells [5].
In this work, we use biological association networks (BANs)
as a tool to define possible targets for gene therapy in combi-
nation with methotrexate (MTX). This approach could serve
to minimize the development of MTX resistance acquired by
cancer cells, which remains a primary cause of therapy
failure in cancer treatment [7]. A role in MTX resistance was
established for the three node genes selected, namely those
encoding Dikkopf homolg 1 (DKK1), UDP-glucuronosyl-
transferases (UGTs; UGT1As) and Eukaryotic translation
elongation factor 1A1 (EEF1A1).
M Me et th ho od ds s
C Ce el ll l   l li in ne es s
Cell lines representative of five types of human cancer were
used: HT29 and Caco-2 for colon cancer, MCF-7 and MDA-
MB-468 for breast cancer, MIA PaCa-2 for pancreatic
cancer, K562 for erythroblastic leukemia, and Saos-2 for
osteosarcoma. These cell lines are sensitive to MTX, with
IC50s of 1.67 x 10-8 M MTX for HT29, 4.87 x 10-8 M MTX for
MDA-MB-468 and 1.16 x 10-8 M MTX for MIA PaCa-2 cells.
IC50 values were calculated using GraphPad Prism 5 version
5.0a for Macintosh (GraphPad Software, San Diego, CA,
USA). Resistant cells were obtained in the laboratory upon
incubation with stepwise concentrations of MTX (Lederle)
as previously described [8]. HT29, Caco-2 and K562
resistant cells were able to grow in 10-5 M MTX; MIA PaCa-2,
Saos-2, MCF-7 and MDA-MB-246 cells were resistant to
10-6 M MTX.
C Ce el ll l   c cu ul lt tu ur re e
Human cell lines were routinely grown in Ham’s F12 medium
supplemented with 7% fetal bovine serum (both from
Gibco/Invitrogen, Grand Island, NY, USA) at 37°C in a 5% CO2
humidified atmosphere. Resistant cells were routinely grown in
selective DHFR medium lacking glycine, hypoxanthine and
thymidine (-GHT medium; Gibco), the final products of
dihydrofolate reductase (DHFR) activity. This medium was
supplemented with 7% dialyzed fetal bovine serum (Gibco).
M Mi ic cr ro oa ar rr ra ay ys s
Gene expression was analyzed by hybridization to the
GeneChip® Human Genome U133 PLUS 2.0 from Affymetrix,
containing over 54,000 transcripts and variants. Total RNA
for oligo arrays was prepared from triplicate samples of every
sensitive and resistant cell line using the RNAeasy Mini kit
(Qiagen, Germantown, Maryland, USA) following the recom-
mendations of the manufacturer. Labeling, hybridization and
detection were carried out following the manufacturer’s
specifications.
M Mi ic cr ro oa ar rr ra ay y   d da at ta a   a an na al ly ys se es s
Gene expression analyses were performed using three samples
of both sensitive and resistant cells for each of the seven cell
lines studied. These analyses were carried out with the
GeneSpring GX software v 7.3.1 (Agilent Technologies, Santa
Clara, CA, USA), using the latest gene annotations available
(March 2009). This software package allows multi-filter
comparisons using data from different experiments to
perform the normalization, generation of restriction (filtered)
lists and functional classifications of the differentially
expressed genes. Normalization was applied in two steps: ‘per
chip normalization’, by which each measurement was divided
by the 50th percentile of all measurements in its array; and
‘per gene normalization’, by which all the samples were
normalized against the median of the control samples
(sensitive cells). The expression of each gene was reported as
the ratio of the value obtained for each condition relative to
the control condition after normalization of the data. Then,
data were filtered using the control strength, a control value
calculated using the Cross-Gene Error model on replicates [9]
and based on average base/proportional value. Measurements
with higher control strength are relatively more precise than
measurements with lower control strength. Genes that did not
reach this value were discarded. Additional filtering was
performed to determine differentially expressed genes. A first
filter was performed by selecting the genes that displayed a P-
value corrected by false discovery rate (Benjamini and
Hochberg false discovery rate) of less than 0.05. The output of
this analysis was then filtered by fold expression. Thus, lists of
genes differentially expressed by at least twofold were
generated for each of the seven resistant cell lines.
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The lists of genes differentially expressed by at least twofold
with a P-value <0.05 including multiple testing correction
for each cell line were divided into two groups: overexpressed
and underexpressed genes. Comparisons of lists of
overexpressed genes were performed using Venn diagrams in
GeneSpring GX. Lists of underexpressed genes were also
compared using the same approach. All lists were compared
in pairs and lists of genes in common between each pair
were generated.
G Ge en ne er ra at ti io on n   o of f   b bi io ol lo og gi ic ca al l   a as ss so oc ci ia at ti io on n   n ne et tw wo or rk ks s
BANs were constructed with the aid of Pathway Architect
software v3.0 (Stratagene-Agilent). Briefly, this software
package generates interaction networks starting with the
genes in a given list (entities) taking into account the
information present in a database of known molecular
interactions. The lists correspond to the collection of
differentially expressed genes under specific conditions. The
database of molecular interactions is composed of more than
1.6 million interactions divided into different classes
(binding, regulation, promoter binding, transport, metabo-
lism, protein metabolism and expression). The interactions
are extracted from the literature using a Natural Language
Processing (NLP) tool run on Medline abstracts (NLP refer-
ences), plus those obtained from external curated databases
like BIND (Biomolecular Interaction Network Database)
[10] and MINT (Molecular INTeraction) [11]. Interactions in
the interaction database are scored according to five
different categories: maximum, high, medium, low and
minimal. Curated interactions (BIND and MINT sources)
are given the maximum quality score, as are any interactions
that have at least three NLP references. Pathway Architect
gathers all that information to construct novel views as to
how the entities in a list could be interacting with each other,
even including entities not present in the original list
(neighbors resulting from the expanded interaction).
Customized analyses were performed to select relevant
interaction networks with an associated high confidence
index since such networks are likely to mirror biological
significance. One-step expansion (using the expand network
command) of the original set of entities with maximum score
interaction were then analyzed by setting an advanced filter
that included the categories of binding, expression, metabo-
lism, promoter binding, protein modification and regulation.
This procedure gives a final representation formed of a
collection of nodes with different degrees of inter-
relationship. Some gene products from the original lists were
not significantly connected with other members or neigh-
bors and, therefore, were removed from the final view.
Finally, members of the network were matched with
expression levels.
T Tr ra an ns sf fe ec ct ti io on n   o of f   s sm ma al ll l   i in nt te er rf fe er ri in ng g   R RN NA As s   a ag ga ai in ns st t   s se el le ec ct te ed d   g ge en ne es s
HT29 cells (30,000) were plated in 1 ml of -GHT medium
and transfection was performed 18 hours later. For each
well, Lipofectamine™ 2000 (Invitrogen, Carlsbad, CA, USA)
in 100 µl of serum free -GHT medium was mixed in
Eppendorf tubes with 100 nM of small interfering RNA
(siRNA) in 100 µl of serum free -GHT medium. The mixture
was incubated at room temperature for 20 minutes before
addition to the cells. MTX (2 x 10-8 M) was added 48 hours
after siRNA treatment and 3-(4,5-Dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT) assays [12] were
performed 3 days after MTX addition. Treatment of MDA-
MB-468 and MIA PaCa-2 cells was performed following the
same protocol but using Metafectene™ (Biontex, Martinsried,
Germany). A non-related siRNA was used as negative
control; it was transfected in parallel with the other siRNAs
and used to normalize the results.
The siRNAs were designed using the software iRNAi v2.1.
(The Netherlands Cancer Institute, Amsterdam, The
Netherlands) Among the possible alternatives, sequences
rich in A/T at the 3’ end of the target were chosen. Then,
BLAST resources in NCBI were used to assess the degree of
specificity of the sequence recognition for these siRNAs.
Only the siRNAs that reported the target gene as the only
mRNA hit, or some family members in the case of siUGT1A,
were selected. The sequences for the sense strand of all
siRNAs used are available in Table 1.
H He ea at t   m ma ap p   g ge en ne er ra at ti io on n
A global comparison of all cell lines was performed using
GeneSpring GX v 7.3.1. The triplicate samples for each
condition in each of the seven cell lines (42 samples) were
imported into one single experiment. Normalization was
performed in two steps: ‘per chip normalization’ (as
described above) and ‘per gene normalization’, by which the
samples were normalized against the median of all samples.
Lists of genes displaying a false discovery rate-corrected P-
value <0.05 were generated for each cell line. As a filter, these
values had to appear in at least two out of the seven cell lines.
A hierarchical clustering method in GeneSpring was used to
group genes on the basis of similar expression patterns over
all samples. The distance matrix used was Pearson
correlation, and average linkage was used as clustering
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S Se en ns se e   s st tr ra an nd d   s se eq qu ue en nc ce es s   o of f   t th he e   s si iR RN NA As s   u us se ed d
Target gene siRNA name siRNA sequence (5’- 3’)
DKK1 siDKK1 AGGTGCTGCACTGCCTATT
UGT1A family siUGT1A GTGCTGGGCAAGTTTACTT
EEF1A1 siEEF1A1 CGGTCTCAGAACTGTTTGT
DHFR siDHFR CCTCCACAAGGAGCTCATT
Luciferase NR-siRNA TAAGGCTATGAAGAGATAC
The sequences for the sense strand of the siRNAs used against the target
genes are provided.algorithm. The same clustering method was used to group the
cell lines on the basis of similar patterns of gene expression.
R Re ea al l- -t ti im me e   R RT T- -P PC CR R
Gene mRNA levels were determined by real-time RT-PCR.
Total RNA was extracted from cells using Ultraspec™ RNA
reagent (Biotecx, Houston, TX, USA) following the recom-
mendations of the manufacturer. For determining gene-
node mRNA levels upon siRNA treatment, cells were treated
as described above and total RNA was prepared 48 hours
after transfection using the same reagent. In either case,
complementary DNA was synthesized in a total volume of
20 µl by mixing 500 ng of total RNA and 125 ng of random
hexamers (Roche, Mannheim, Germany) in the presence of
75 mM KCl, 3 mM MgCl2, 10 mM dithiothreitol, 20 units of
RNasin (Promega, Madison, WI, USA), 0.5 mM dNTPs
(AppliChem, Darmstadt, Germany), 200 units of M-MLV
reverse transcriptase (Invitrogen) and 50 mM Tris-HCl
buffer, pH 8.3. The reaction mixture was incubated at 37ºC
for 60 minutes. The cDNA product was used for subsequent
real-time PCR amplification using an ABI Prism 7000
Sequence Detection System (Applied Biosystems, Foster
City, CA, USA) with 25 ng of the cDNA mixture, the assays-
on-demand from Applied Biosystems Hs00758822_s1 for
DHFR and Hs00356991_m1 for Adenine Phosphoribosyl-
transferase (APRT) or the following primers: DKK1, 5’-AGT-
ACTGCGCTAGTCCCACC-3’ and 5’-CTGGAATACCCATCC-
AAGGTGC-3’;  UGT1A, 5’-TAAGTGGCTACCCCAAAACG-3’
and 5’-CTCCAGCTCCCTTAGTCTCC-3’; EEF1A1, 5’-CGT-
CATTGGACACGTAGATTCGGG-3’ and 5’-GGAGCCCTT-
TCCCATCTCAGC-3’.
G Ge en ne e   c co op py y   n nu um mb be er r   d de et te er rm mi in na at ti io on n
Genomic DNA from either sensitive or resistant cells was
obtained with the Wizard™ Genomic DNA Purification Kit
(Promega) following the manufacturer’s recommendations.
One hundred nanograms of DNA and the assays-on-demand
Hs00758822_s1 for DHFR and Hs99999901_s1 for 18S
were used for real-time PCR amplification.
P Pr re ep pa ar ra at ti io on n   o of f   t to ot ta al l   e ex xt tr ra ac ct ts s   f fo or r   w we es st te er rn n   b bl lo ot tt ti in ng g
Total extracts from cells, either sensitive or MTX-resistant,
were used to assay DHFR protein levels. Cells were washed
twice with ice-cold phosphate-buffered saline and scraped in
200 ml lysis buffer (50 mM Hepes, 500 mM NaCl, 1.5 M
MgCl2, 1 mM EGTA, 10% glycerol (v/v), 1% Triton X-100 and
protease inhibitor cocktail). Cells were incubated in ice for 1
hour with vortexing every 15 minutes and then centrifuged
at 14,000 rpm at 4°C for 10 minutes. Five microliters of the
extract were used to determine protein concentration by the
Bradford assay (Bio-Rad, Munich, Germany). The extracts
were frozen in liquid N2 and stored at -80°C. Fifty micro-
grams of both sensitive and resistant cell total extracts were
resolved by 15% SDS-PAGE. Transference to PVDF mem-
branes (Immobilon P, Millipore, Bedford, MA, USA) using a
semidry electroblotter was followed by incubation with an
antibody against DHFR (Davids Biotechnologie, Regensburg,
Germany), and detection was accomplished using secondary
horseradish peroxidase-conjugated antibody and enhanced
chemiluminescence, as recommended by the manufacturer
(Amersham/GE Healthcare, Buckinghamshire, UK). To
normalize the results, blots were re-probed with an antibody
against actin (Sigma, St. Louis, MO, USA).
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F Fi ig gu ur re e   1 1
Heat map of differentially expressed genes. Lists of differentially
expressed genes with a t-test P-value <0.05 including multiple testing
correction were generated for each cell line. A hierarchical clustering
method in GeneSpring GX v 7.3.1 was used to construct both the gene
tree and the sample tree, as described in Methods. Data are shown in a
matrix format: each row represents a single gene, and each column
represents a cell line. Red indicates overexpressed genes (expression
levels over the median) and green indicates underexpressed genes
(expression levels under the median; see legend). The pattern and length
of the branches in the dendrograms reflect the relatedness of the samples
or the genes.
-
S
H
T
2
9
 
R
C
a
C
o
-
2
 
S
C
a
C
o
-
R
M
C
F
-
7
 
-
S
M
C
F
-
-
R
M
D
A
-
M
B
 
-
S
M
D
A
-
M
B
 
-
R
M
I
A
 
P
a
C
a
-
-
S
M
I
A
 
P
a
C
a
-
R
K
5
6
2
-
S
K
5
6
2
R
S
a
O
s
-
2
 
-
S
S
a
O
s
-
2
 
-
R
C
o
l
o
n
 
c
a
n
c
e
r
B
r
e
a
s
t
 
c
a
n
c
e
r
O
s
t
e
o
s
a
r
c
o
m
a
L
e
u
k
e
m
i
a
P
a
n
c
r
e
a
t
i
c
 
c
a
n
c
e
r
H
T
2
9
 
-
-
2
 
-
7
 
-
2
2
-
-
-
-
-T Tr ra an ns sf fe ec ct ti io on ns s, ,   c co o- -t tr ra an ns sf fe ec ct ti io on ns s   a an nd d   l lu uc ci if fe er ra as se e   a as ss sa ay ys s
HT29 cells, either sensitive or MTX-resistant, were seeded
into six-well plates the day before transfection at a density of
2 x 105 cells/well in Ham’s F12 medium containing 7% fetal
bovine serum. Transfection was performed using FUGENE™
HD (Roche). For each well, 6 µl of FUGENE™ HD in 100 µl
of serum-free medium was incubated at room temperature
for 5 minutes. The mixture was added to 1 µg of TOPFLASH
(Millipore) and incubated at room temperature for
20 minutes before addition to the cells. In co-transfections,
1 µg of TOPFLASH was mixed together with 2 µg of
pBATEM2-CDH before the addition of FUGENE™ HD in
serum-free medium. The total amount of DNA was kept
constant at 3 µg, adding empty vector when necessary.
Luciferase activity was assayed 30 hours after transfection.
In all cases, cell extracts were prepared by lysing the cells
with 200 µl of freshly diluted 1x Reporter Lysis Buffer
(Promega). The lysate was centrifugated at 13,000 g for
2 minutes to pellet the cell debris and the supernatants were
transferred to a fresh tube. A 15-µl aliquot of the extract was
added to 15 µl of the luciferase assay substrate (Promega)
and the luminiscence of the samples was read immediately
on a Gloomax 20/20 luminometer (Promega); light produc-
tion (relative light units) was measured for 10 s. Each trans-
fection was performed in triplicate. Protein concentration
was determined by the Bradford assay and used to normalize
the results.
S St ta at ti is st ti ic ca al l   a an na al ly ys se es s
Data are presented as mean ± standard error (SE). Statistical
analyses were performed using the unpaired t-test option in
GraphPad InStat version 3.1a for Macintosh (GraphPad
Software). P-values <0.05 were considered to be statistically
significant.
R Re es su ul lt ts s
G Ge en ne es s   d de er re eg gu ul la at te ed d   i in n   m me et th ho ot tr re ex xa at te e- -r re es si is st ta an nt t   c ca an nc ce er r   c ce el ll l   l li in ne es s
In a previous study, we analyzed the differential gene expres-
sion between sensitive and MTX-resistant cells derived from
the human colon cancer cell line HT29 [13]. In the present
work we extend the study of gene expression profiles
associated with MTX resistance by including another six
MTX-resistant cell lines. Together, the studied cell lines
represent colon cancer (CaCo2 and HT29), breast cancer
(MCF-7 and MDA-MB-468), pancreatic cancer (MIA
PaCa-2), erythroblastic leukemia (K562) and osteosarcoma
(SaOs-2). Total RNA was extracted for the seven pairs of
sensitive and MTX-resistant cell lines, and the expression
profile of the 54,700 transcripts and variants included in the
HG U133 PLUS 2.0 microarray from Affymetrix was
compared between each pair using GeneSpring GX software
v7.3.1. Upon normalization and statistical filtering of the
data, lists of genes differentially expressed by at least
twofold were built as described in Methods. These lists are
presented as Additional data files 1 to 7. The data discussed
in this report have been deposited in the Gene Expression
Omnibus (GEO) [14] and are accessible through GEO series
accession number [GSE16648].
H Hi ie er ra ar rc ch hi ic ca al l   c cl lu us st te er ri in ng g   o of f   g ge en ne es s   a an nd d   c ce el ll l   l li in ne es s
We compared the gene expression patterns of all the studied
cell lines together. Lists of genes displaying a false discovery
rate-corrected  P-value <0.05 were generated for each cell
line. Then, hierarchical clustering in GeneSpring GX was
used to construct a heat map displaying both a gene tree and
a sample tree (Figure 1), as described in Methods. Two facts
could be extracted from this representation. First, there is a
high correlation between cell lines sharing the same tissue
origin. The two colon cancer cell lines studied (HT29 and
Caco-2) are more highly correlated in gene expression with
each other than with all the other cell lines. The breast
cancer cell lines studied (MCF-7 and MDA-MB-468) also
showed similar gene expression, although the degree of
correlation is slightly lower than that for the colon cancer
cell lines. The other three cell lines studied (MIA PaCa-2,
K562 and Saos-2) displayed different gene expression from
the colon or the breast cancer cell lines, and thus cluster
apart from them. Second, gene expression of the resistant
cells is more closely correlated with that of their sensitive
cell counterparts than with any other sample or cell line.
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T Ta ab bl le e   2 2
V Va al li id da at ti io on n   o of f   d dh hf fr r o ov ve er re ex xp pr re es ss si io on n   a an nd d   c co op py y   n nu um mb be er r   d de et te er rm mi in na at ti io on n   i in n   t th he e
d di if ff fe er re en nt t   c ce el ll l   l li in ne es s
Expression
RT-PCR 
Cell line Microarray validation Copy number Protein
HT29 7.1 10.8 ± 0.7 16.1 ± 1.4 ++
Caco-2 46.7 49.7 ± 1.1 83.4 ± 8.1 ND
MCF-7 31.1 33.2 ± 0.7 58.1 ± 0.8 +++++
MDA-MB-468 1.8 3.4 ± 0.1 0.9 ± 0.1 ND
MIA PaCa-2 9.5 8.2 ± 1.1 32.2 ± 2.2 +++
K562 9.4 9.8 ± 0.2 1.9 ± 0.1 ++++
Saos-2 4.1 4.1 ± 1.1 0.6 ± 0.1 +
The overexpression of DHFR was validated at the mRNA and protein
levels by real-time RT-PCR and western blotting using a specific antibody,
respectively. DHFR expression levels are presented both as the values
found in the microarrays and as validated by RT-PCR. dhfr copy number
was determined by real-time PCR. Values are the mean (in fold change
relative to the sensitive cells) of three independent experiments ± SE.
Protein levels were qualitatively assessed (+ to +++++) from the western
blot images. ND, non-determined.http://genomemedicine.com/content/1/9/83 Genome Medicine 2009, Volume 1, Issue 9, Article 83 Selga et al. 83.6
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G Ge en ne es s   d di if ff fe er re en nt ti ia al ll ly y   e ex xp pr re es ss se ed d   i in n   c co om mm mo on n   a am mo on ng g   c co ol lo on n   c ca an nc ce er r   c ce el ll l   l li in ne es s   r re es si is st ta an nt t   t to o   M MT TX X
GenBank ID Gene name Description Ratio HT29 Ratio Caco-2
AI144299 DHFR Dihydrofolate reductase 7.25 46.35
BC005238 FXYD3 FXYD domain containing ion transport regulator 3 7.24 2.20
BC003584 DHFR Dihydrofolate reductase 6.96 50.23
BC000192 DHFR Dihydrofolate reductase 6.89 38.31
NM_002380 MATN2 Matrilin 2 6.62 4.70
BU078629 ZFYVE16 Zinc finger, FYVE domain containing 16 6.06 22.73
NM_001975 ENO2 Enolase 2 (gamma, neuronal) 5.98 2.04
NM_017954 CADPS2 Ca2+-dependent activator protein for secretion 2 5.60 2.27
AI991103 AXIIR Similar to annexin II receptor 5.14 2.03
NM_000791 DHFR Dihydrofolate reductase 4.71 21.17
U05598 AKR1C2 Aldo-keto reductase family 1, member C2 4.63 10.15
M33376 AKR1C2 Aldo-keto reductase family 1, member C2 4.41 8.89
NM_012242 DKK1 Dickkopf homolog 1 4.25 2.56
NM_014867 KBTBD11 Kelch repeat and BTB (POZ) domain containing 11 4.22 2.14
AB037848 KIAA1427 Synaptotagmin XIII 4.13 9.56
NM_014733 ZFYVE16 Zinc finger, FYVE domain containing 16 4.11 15.6
NM_001353 AKR1C1 Aldo-keto reductase family 1, member C1 3.94 8.87
NM_002439 MSH3 MutS homolog 3 3.87 4.00
S68290 AKR1C1 Aldo-keto reductase family 1, member C1 3.66 9.45
J04810 MSH3 MutS homolog 3 3.27 8.23
NM_000691 ALDH3A1 Aldehyde dehydrogenase 3 family, member A1 2.86 3.81
AI718385 SLC26A2 Solute carrier family 26 member 2 2.76 2.02
NM_003069 SMARCA1 SWI/SNF related, regulator of chromatin a1 2.60 2.49
AB029026 TACC1 Transforming, acidic coiled-coil containing protein 1 2.35 3.89
NM_006283 TACC1 Transforming, acidic coiled-coil containing protein 1 2.31 3.26
AF188298 DAB2 Disabled homolog 2 2.29 2.11
NM_020299 AKR1B10 Aldo-keto reductase family 1, member B10 2.26 22.95
BC006471 MLLT11 Myeloid/lymphoid or mixed-lineage leukemia 2.18 2.60
W93554 SH3PXD2A SH3 and PX domains 2A 2.14 3.45
NM_014778 NUPL1 Nucleoporin like 1 0.46 0.43
NM_006033 LIPG Lipase, endothelial 0.40 0.42
NM_012338 TM4SF12 Transmembrane 4 superfamily member 12 0.39 0.38
NM_007150 ZNF185 Zinc finger protein 185 (LIM domain) 0.38 0.42
AB014605 MAGI2 Membrane associated guanylate kinase 0.38 0.30
AB033831 SCDGF Platelet derived growth factor C 0.35 0.35
NM_021021 SNTB1 Syntrophin, beta 1 0.35 0.23
NM_021822 APOBEC3G Apolipoprotein B, catalytic polypeptide-like 3G 0.30 0.08
AB039791 ARP11 Actin-related protein Arp11 0.29 0.46
NM_013352 SART2 Squamous cell carcinoma antigen 0.22 0.31
Continued overleafD Di ih hy yd dr ro of fo ol la at te e   r re ed du uc ct ta as se e   s st ta at tu us s   i in n   a al ll l   c ce el ll l   l li in ne es s   s st tu ud di ie ed d
As DHFR is the target for MTX, and was upregulated in
MTX-resistant cells, we validated its overexpression in all
cell lines studied. Real-time RT-PCR was used to quantify
the mRNA levels, and DHFR protein levels were determined
by western blotting in both sensitive and MTX-resistant cell
lines (Table 2). Copy number determination revealed dhfr
amplification only in HT29, Caco-2, MCF-7 and MIA
PACA-2 resistant cells (Table 2).
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Lists of genes differentially expressed by at least twofold
between sensitive and resistant cell lines were generated for
each cell line. Each list was split in two, one group including
the overexpressed genes and the other including the
underexpressed genes. Then, Venn diagrams were used to
compare the lists of overexpressed and underexpressed
genes between HT29 and Caco-2 cell lines, between MCF-7
and MDA-MB-468 cell lines, and among MIA PaCa-2, K562
and Saos-2 cell lines (Tables 3, 4 and 5, respectively). This
approach allowed us to identify differentially expressed
genes with a common trend in expression among the cell
lines compared.
D De et te ec ct ti io on n   o of f   n no od de es s   u up po on n   g ge en ne er ra at ti io on n   o of f   b bi io ol lo og gi ic ca al l   a as ss so oc ci ia at ti io on n
n ne et tw wo or rk ks s
BANs were constructed using the Pathway Architect soft-
ware as described in Methods starting with the lists of genes
differentially expressed in common between both colon
cancer cell lines, both breast cancer cell lines and among the
pancreas cancer, leukemia and osteosarcoma cell lines
(Figure 2a,b,c, respectively). In the BANs generated, DKK1 is
a highly interconnected node in the colon cancer cell lines,
UGT1A family members formed a network of genes
differentially expressed in breast cancer, and EEF1A1 was
commonly overexpressed in pancreatic cancer, leukemia and
osteosarcoma. A BAN including all the genes of the three
lists of differentially expressed genes was constructed
(Figure 3).  DKK1,  UGT1A and  EEF1A1 all seemed to be
important nodes of this newly constructed network, and thus
were selected for further study.
E Ef ff fe ec ct t   o on n   M MT TX X   s se en ns si it ti iv vi it ty y   o of f   s si iR RN NA As s   d de es si ig gn ne ed d   a ag ga ai in ns st t   t th he e
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Given that the node genes DKK1, UGT1As and EEF1A1 were
overexpressed in cells resistant to MTX (Table 6), we investi-
gated the effect of decreasing their mRNA levels by means of
siRNAs on the sensitivity to this chemotherapeutic agent.
We also performed treatments with siDHFR in order to
assess the role of DHFR in MTX resistance. HT29 and MDA-
MB-468 cell lines were used as models of colon and breast
cancer, respectively, and MIA PaCa-2 cells were selected as
the model for the other three cell lines. Previously, it was
confirmed that the mRNA levels of the three genes were
decreased 48 hours after siRNA treatment (Figure 4a-c).
Cells were pre-incubated with individual siRNAs for 48 hours
before the addition of methotrexate. The presence of 100 nM
of either siDKK1 or siDHFR caused increases in MTX cyto-
toxicity in HT29 cells of 50% and 65%, respectively, com-
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GenBank ID Gene name Description Ratio HT29 Ratio Caco-2
NM_004362 CLGN Calmegin 0.21 0.19
AI912583 GLIPR1 GLI pathogenesis-related 1 (glioma) 0.21 0.45
Z19574 KRT17 Keratin 17 0.19 0.46
NM_003186 TAGLN1 Transgelin 0.19 0.14
NM_014059 RGC32 Response gene to complement 32 0.17 0.44
BE872674 CLEC3A C-type lectin domain family 3, member A 0.15 0.24
NM_003212 TDGF1/3 Teratocarcinoma-derived growth factor 1/3 0.13 0.47
BC000069 RARRES2 Retinoic acid receptor responder 2 0.07 0.33
AF110400 FGF19 Fibroblast growth factor 19 0.06 0.26
NM_006851 GLIPR1 GLI pathogenesis-related 1 0.05 0.28
NM_006169 NNMT Nicotinamide N-methyltransferase 0.04 0.24
AF208043 IFI16 Interferon, gamma-inducible protein 16 0.03 0.38
BG256677 IFI16 Interferon, gamma-inducible protein 16 0.02 0.40
NM_006169 NNMT Nicotinamide N-methyltransferase 0.02 0.24
Genes differentially expressed by at least twofold with a P-value <0.05 including multiple testing correction were compared between HT29 and Caco-2
cells using Venn diagrams in GeneSpring GX software v 7.3.1. The table includes the GenBank IDs for all genes, their respective common names and the
associated description. The ratio column corresponds to the fold change in expression of each gene relative to its sensitive counterpart.pared to MTX alone (Figure 4d). Incubation with 100 nM of
either siUGT1A or siDHFR in MDA-MB-468 cells caused
increases in cytotoxicity of 36% and 50%, respectively, com-
pared to MTX alone (Figure 4e). Treatment of MIA PaCa-2
cells with 30 nM of either siEEF1A1 or siDHFR resulted in
increased cytotoxicity of 35% and 65%, respectively, com-
pared to MTX alone (Figure 4f). The same approach was
conducted in the resistant counterparts of the HT29, MDA-
MB-468 and MIA PaCa-2 cell lines, but no significant changes
in cytotoxicity were observed (P > 0.05; data not shown).
Given that the UGT1A family is involved in the metabolism
of other drugs, we also performed combination treatments
with siUGT1A and SN38, the active metabolite of the
anticancer drug irinotecan. Transfection of the siRNA was
performed as described above, and 1 nM SN38 was added
48 hours after siRNA treatment. These incubations led to a
significant (P < 0.01) increase of 46% in SN38 sensitivity.
A non-related siRNA against the luciferase gene was used as
a negative control in all experiments. Transfection of this
siRNA was performed in parallel with the other siRNAs, and
was used to normalize the results.
D DK KK K1 1   i is s   o ov ve er re ex xp pr re es ss se ed d   i in n   H HT T2 29 9   M MT TX X- -r re es si is st ta an nt t   c ce el ll ls s   d du ue e   t to o
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As DKK1 is known to be transcriptionally regulated by the
Wnt pathway, we investigated the degree of activation of this
signaling pathway in MTX-resistant HT29 cells compared
with their sensitive counterpart. Cells were transiently
transfected with the reporter plasmid TOPFLASH, bearing
three T-cell factor (TCF) binding sites. A transcriptional
activation of 26-fold resulted from the transfection of
TOPFLASH in the resistant cells, while no significant
activation was observed upon transfection in the sensitive
cells (Figure 5). Additionally, co-transfections of TOPFLASH
with an expression plasmid for E-cadherin (pBATEM2-
CDH) were performed in both cell lines. As shown in Figure
5, overexpression of E-cadherin in the resistant cells led to a
marked decrease in TOPFLASH activity, down to basal
activity. No significant changes in transcriptional activity
were observed when these co-transfections were performed
in the sensitive cells.
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GenBank Gene name Description MCF7 MDA-MB-
468
NM_019093 UGT1A1/3/4/5/6/7/8/9/10 UDP glucuronosyltransferase 1, polypeptides A1/3/4/5/6/7/8/9/10 24.36 27.93
NM_000463 UGT1A1/4/6/8/9/10 UDP glucuronosyltransferase 1, polypeptides A1/4/6/8/9/10 15.31 17.66
NM_021027 UGT1A1/4/6/8/9/10 UDP glucuronosyltransferase 1, polypeptides A1/4/6/8/9/10 13.55 17.05
NM_001072 UGT1A1/3/4/5/6/7/8/9/10 UDP glucuronosyltransferase 1, polypeptides A1/3/4/5/6/7/8/9/10 13.21 16.88
AV691323 UGT1A1/3/4/5/6/7/8/9/10 UDP glucuronosyltransferase 1, polypeptides A1/3/4/5/6/7/8/9/10 13.05 16.82
Genes differentially expressed by at least twofold with a P-value <0.05 including multiple testing correction were compared between MCF7 and
MDA-MB-468 cells as described in Table 3.
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GenBank Gene name Description Ratio MIA PaCa-2 Ratio K562 Ratio Saos-2
BC003584 DHFR Dihydrofolate reductase 16.97 17.78 4.06
BC000192 DHFR Dihydrofolate reductase 12.56 13.57 5.28
AI144299 DHFR Dihydrofolate reductase 12.1 9.45 8.94
NM_000791 DHFR Dihydrofolate reductase 9.66 6.76 5.57
BE622627 PIK3R3 Phosphoinositide-3-kinase, regulatory subunit 3 5.23 2.09 4.44
AW469790 EEF1A1 Eukaryotic translation elongation factor 1 alpha 1 2.29 2.75 2.05
NM_012446 SSBP2 Single-stranded DNA binding protein 2 2.2 5.04 2.03
AF318326 APG10L ATG10 autophagy related 10 homolog  2.08 7.39 2.19
Genes differentially expressed by at least twofold with a P-value <0.05 including multiple testing correction were compared between MIA PaCa-2, K562
and Saos-2 cells as described in Table 3.http://genomemedicine.com/content/1/9/83 Genome Medicine 2009, Volume 1, Issue 9, Article 83 Selga et al. 83.9
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BANs of differentially expressed genes in common between cell lines. The lists of common genes between both colon cancer cell lines, between both
breast cancer cell lines, and among the other three cell lines studied (representative of pancreatic cancer, leukemia and osteosarcoma) were used to
construct BANs with the Pathway Architect software. Expanded networks were constructed for each list - ( (a a) ) colon cancer, ( (b b) ) breast cancer and ( (c c) ) the
other three cell lines - by setting an advanced filter that included the categories of binding, expression, metabolism, promoter binding, protein
modification and regulation (see legend). Only proteins are represented. Overlapping of the expression levels was also performed (red for overexpressed
genes and green for underexpressed genes; translucent shading represents genes that were not in the list and were added by the program from the
interactions database). The BANs show some node genes that were studied further (those with arrows pointing to them).
(a)
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BAN of all common genes. A BAN was constructed as previously described with all the genes included in any of the three lists of common genes
(encircled in blue). Genes added by the program from the interaction database are not outlined. Node genes are those with arrows pointing to them.
LegendD Di is sc cu us ss si io on n
The main objective of this work was to explore whether node
genes could be identified from BANs constructed starting
from genes differentially expressed in MTX-resistant cells
from different human cancer cell lines, representative of five
tissues. Those putative node genes may then be used as
targets to increase the sensitivity toward MTX.
We started by determining and comparing the patterns of
differential gene expression associated with MTX resistance
in seven cell lines. The only differentially expressed gene in
common among all the cell lines studied was dhfr. Its over-
expression, at both the mRNA and protein levels, was
confirmed in the MTX-resistant cells studied. The mRNA
upregulation can be explained either by gene amplification
of the dhfr  locus, a well recognized mechanism for MTX
resistance [15-17], or by an increase of dhfr transcription
rate. In accordance with this, HT29, CaCo-2, MCF-7 and
MIA PACA-2 resistant cells display an increased dhfr copy
number. Indeed, amplification of the 5q14 locus, including
dhfr and flanking genes, has been described in HT29 MTX-
resistant cells [13]. On the other hand, the other cell lines
studied bear no changes in dhfr copy number. Thus, drug
resistance in MDA-MB-468, K562 and Saos-2 cells may be
caused by any of the other known mechanisms for MTX
resistance [18-22]. Additionally, one has to take into account
that MTX causes the differential expression of many genes
that may be direct or indirect regulators of cell proliferation,
survival or apoptosis, and that this expression pattern can
contribute to modulation of the resistance phenotype. As
described in this work, the overexpression of DKK1, UGT1As
or EEF1A1 could represent a mechanism, parallel to DHFR
overexpression, that plays a role in MTX resistance; the
possible contribution of the overexpression of each of these
genes is addressed below. Other work has determined genes
that correlate with the capability of parental cells to resist
treatment using concentrations assessed to be clinically
achievable in tumor tissue [23]. Although this approach is
different to the goal of our work, to identify genes differen-
tially expressed in cells with acquired resistance to high
concentrations of MTX, we compared the results obtained by
Gyorffy  et al. [23] with ours and found only six genes in
common, namely CD99,  CKMT1,  DHRS2,  IGFBP7,  MAP7
and MYO1E.
Hierarchical clustering of all samples indicated that the
MTX-resistant cells and their sensitive counterparts were
highly correlated with regards to gene expression with each
other. This is in accordance with reports showing that two
breast tumor samples from the same patient before and after
treatment with doxorubicin pair together in a hierarchical
clustering [24]. Moreover, the same authors proposed that
the molecular program of a primary tumor could generally
be retained in its metastases. Similar results were obtained
with leukemic cells from patients [25].
Interestingly, as shown in Figure 1, the gene expression
patterns for the cell lines from the same tissue origin were
very similar. Sets of coordinately expressed genes provide
gene expression signatures that can indicate where to find
targets suitable for gene therapy. Thus, we generated a list of
genes differentially expressed in common between the two
colon cancer cell lines. This list included, among others,
genes encoding DHFR, the target for MTX, three members
of the AKR family and ENO2, which we have previously
studied as modulators of MTX resistance [8,13], and DKK1.
BAN construction using the genes differentially expressed in
common between both colon cancer cell lines identified
DKK1 as a highly interconnected node of the network, which
could as such be a candidate druggable gene. DKK1 is a
secreted protein involved in embryonic development [26]
and is classically considered to function as an inhibitor of the
canonical Wnt signaling pathway [27] (see [28] for a review).
However, it does not take an active part in the Wnt/β-
catenin pathway in colon cancer cells, as mutation of adeno-
matous polyposis coli (one of the components of Wnt path-
way) occurs in most human colon cancers [29,30], thus
disconnecting the effector part of the signaling cascade from
the Wnt receptors, where DKK1 exerts its inhibitory effect
[31,32]. This situation led us to hypothesize that DKK1 could
have other cellular functions aside from its role in the Wnt
pathway. Indeed, a role for DKK1 overexpression in cancer
[26], including hepatobastomas [33] and breast cancer bone
metastasis [34], aggressive tumors, epithelial-mesenchymal
transition [35] and proliferation [36], has been previously
suggested, although its precise mechanism of action has not
yet been elucidated. In the case of HT29 MTX-resistant cells,
the role of DKK1 is unclear, although it seems to be related
to the resistant phenotype, since treatment with the siRNA
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Expression
Gene Cell line Microarray RT-PCR validation
DKK1 HT29 4.25 5.66 ± 0.23
Caco-2 2.56 1.96 ± 0.03
UGT1A MCF-7 15.90 23.41 ± 0.94
MDA-MB-468 19.27 16.28 ± 0.19
EEF1A1 MIA PaCa-2 2.29 3.89 ± 0.16
K562 2.75 2.38 ± 0.47
Saos-2 2.05 1.85 ± 0.15
The expression levels for the three node genes (DKK1, UGT1A and
EEF1A1) derived from both the microarray data (average of the
overexpressed UGT1A family members) and real-time RT-PCR are given.
All the results are expressed as fold changes relative to the sensitive cells
and values are the mean of triplicate experiments ± SE.against DKK1 mRNA showed a chemosensitization toward
MTX. In keeping with this, Katula and collaborators [37]
showed that folate deficiency led to the downregulation of
DKK1, and that MTX inhibited DKK1 transcription. Thus,
DKK1 overexpression in HT29 MTX-resistant cells could
constitute a mechanism to overcome the transcriptional
repression exerted by MTX.
It is worth noting that we had previously proposed the
activation of the Wnt/ß-catenin pathway to be an important
step in MTX resistance in HT29 colon cancer cells [13]. In
this cell line, E-cadherin is chromosomically lost and
underexpressed, thus allowing β-catenin to play its function
in gene transcription. In order to shed some light on the
possible role of the Wnt pathway in the overexpression of
DKK1 in HT29 resistant cells, we performed transient trans-
fection experiments with a luciferase reporter of β-catenin-
mediated transcriptional activation. These experiments
showed that the Wnt pathway was more active in the HT29
resistant cells than in HT29 sensitive cells, and that re-
expression of E-cadherin in the resistant cells resulted in
lower β-catenin-mediated transcriptional activation, probably
due to recruitment of β-catenin to the adherent junctions.
Interestingly, DKK1 is transcriptionally regulated by Wnt/β-
catenin signaling. Thus, constitutive activation of this signal-
ing pathway through β-catenin, downstream of adenoma-
tous polyposis coli, could represent a mechanism for DKK1
overexpression in HT29 MTX-resistant cells.
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Effects on MTX sensitivity of treatment with siRNAs against DKK1, UGT1As or EEF1A1. ( (a a- -f f) ) Treatment with siDKK1 was performed in HT29 cells
(a,d), siUGT1A was transfected in MDA-MB-468 cells (b,e) and the effects of siEEF1A1 were determined in MIA PaCa-2 cells (c,f). Treatments were
performed as described in Methods, and MTX was added after 48 h. Cell viability was determined 3 days after MTX treatment (d-f). (d-f) A siRNA
against dhfr was transfected in each of the three cell lines, and its effects on cell viability are presented. For determination of mRNA levels, real-time RT-
PCR was performed with 500 ng of total RNA extracted 48 h after siRNA transfection (a-c). All results are expressed as percentages relative to the non-
related negative control siRNA (NR-siRNA). Values are the mean of three independent experiments ± SE. *P < 0.05, **P < 0.01 and ***P < 0.001.
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(f)UGT1As were the only genes differentially expressed in
common between both breast cancer cell lines analyzed. UGTs
comprise a family of membrane glycoproteins that come from
one single gene located on chromosome 2q37, rendering nine
functional UGT1A proteins by alternative splicing of 13
different first exons with the common exons 2 to 5 [38]. UGTs
are involved in phase II metabolism of a wide range of
metabolites, both endogenous and exogenous [39].
Glucuronidation is an important metabolic process, as it
carries out the biotransformation of lipophilic substrates into
hydrophilic glucuronides, which can be more easily removed
from the body. Among the different products that can undergo
glucuronidation, we find analgesics, sex hormones, flavonoids,
rifampicin, bilirubin and tobacco-specific carcinogens [40,41].
Some anticancer drugs, such as topotecan, irinotecan, SN-38
(the active metabolite of irinotecan), doxorubicin and 4-
hydroxytamoxifen, have also been described to be substrates
of UGT1A activity [42-47]. Metabolism by UGT1A family
members has been described to induce resistance toward
daunorubicin (in both cell lines and rat hyperplastic liver
nodules) [48,49], mycophenolic acid [50,51], mitoxantrone
[52], SN-38 [53,54], camptothecin [55] and other drugs
[56,57]. Indeed, drug inactivation by metabolism within
tumor cells is recognized as an important mechanism of drug
resistance, and, specifically, glucuronidation by UGT enzymes
has been proposed to contribute to multidrug resistance of
several chemotherapeutic drugs [56]. From our results using a
siRNA against UGT1A mRNA we can point out a role for this
family of genes in MTX resistance in MDA-MB-468 breast
cancer cells. In fact, Hanioka et al. [58] reported that β-
naphthoflavone induced UGT1A mRNA levels. This could be a
feasible explanation for the UGT1A overexpression we
observed in the breast cancer MTX-resistant cells used in our
study.
EEF1A1 was overexpressed in common among MIA PaCa-2,
K562 and Saos-2 resistant cell lines. EEF1A1 is a ubiquitously
expressed protein elongation factor that recruits amino-
acetylated tRNAs to the A site of the ribosome (see [59] for a
review). Although it has been traditionally described as a
cellular housekeeper enzyme, overexpression of EEF1A1 is
found in melanomas and tumors of the pancreas, breast, lung,
prostate and colon [59,60]. It has been demonstrated that
EEF1A expression is related to increased cell proliferation
[61,62], oncogenic transformation [63], delayed cell
senescence [64] and metastasis [65]. Moreover, increased
EEF1A1 expression has been related to cisplatin [66],
doxorubicin [67] and MTX resistance [68], maybe due to its
ability to inhibit apoptosis [69]. It has been proposed that
EEF1A overexpression promotes cell growth and replication
by contributing to an overall increase in protein translation.
Antisense-mediated abrogation of EEF1A1 expression inhibits
tumorigenesis and anchorage-independent cell replication in
prostate tumor cells [70]. Our functional analyses using siRNA
technology against EEF1A1 are in keeping with these results,
and show a chemosensitization of MIA PaCa-2 cells, thus
stating a role for EEF1A1 in MTX resistance in this cell line.
In summary, our results provide evidence that node genes can
be identified by constructing BANs with lists of genes
differentially expressed in common between cell lines
resistant to MTX. RNA interference technology has enabled us
to demonstrate a role for DKK1, UGT1As and EEF1A1 in MTX
resistance.
C Co on nc cl lu us si io on ns s
BANs were constructed using genes differentially expressed in
common between cells resistant to MTX from seven human
cancer cell lines representative of five tissues. We have been
able to identify important node genes in the BANs, namely
DKK1 in colon cancer cells, UGT1As in breast cancer cells and
EEF1A1 in pancreatic cancer, leukemia and osteosarcoma
cells. These three genes were functionally validated using
siRNAs against their respective mRNAs, which resulted in
increased sensitivity to MTX.
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Transcriptional activation of the Wnt pathway in MTX-resistant cells
leads to DKK1 overexpression. HT29 cells, either sensitive or resistant,
were transiently transfected with 1mg of a luciferase reporter of b-
catenin-mediated transcriptional activation (TOPFLASH) using Fugene™
HD in the presence or absence of 2 mg of E-cadherin expression vector
(pBATEM2-CDH). Thirty hours after transfection, luciferase activity
(relative light units (RLU)) was assayed. The protein content was used to
normalize the luciferase activity for each sample and is expressed relative
to that of pGL3 basic vector (mean ± standard error of the mean for
triplicate wells). *P < 0.05.
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APRT = Adenine Phosphoribosyltransferase; BAN = biological
association network; DHFR = dihydrofolate reductase; DKK1
= Dikkopf homolog 1; EEF1A1 = eukaryotic translation
elongation factor 1 alpha 1; MTT = 3-(4,5-Dimethylthiazol-2-
yl)-2,5-diphenyltetrazolium bromide; MTX = methotrexate;
NLP = Natural Language Processing; SE = standard error;
siRNA = small interfering RNA; TCF = T-cell factor; UGT =
UDP glucuronosyl transferase.
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